Skip to main content Skip to main content
Go to homepage
Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Treating Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Description:

For complete study information, please view the study on clinicaltrials.gov.

Study Status:
Closed
Full IRB Study Title:
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
IRB Study ID:
1038450-1
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research, Shannon E. Wilkes Targeted Therapy Program; The Jeffrey A. Barbour Chair for Pediatric Hematology/Oncology Research and Healing; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program

Starting Locations:
Career Opportunities
Legal:
Mobile App:

Akron Children's Anywhere:

About Akron Children's

While we are ranked among the best children's hospitals in the country, it's our compassionate approach to treatment that makes us truly exceptional. Through a combination of revolutionary treatments and extraordinary patient experiences, our care does more than heal. It brings the entire family together for emotional support and understanding across multiple locations to reach you in the community where you live. Learn more...

Akron Children's
One Perkins Square, Akron, Ohio 44308-1062
330-543-1000 • webmaster@akronchildrens.org
An Equal Opportunity Employer
Copyright © 2020, Akron Children's. All Rights Reserved.
  • Magnet Recongnition
  • Newsweek: World's Best Hospitals - 2023
  • Newsweek: World's Best Hospitals - Pediatrics 2023

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.